Andrea Necchi

Andrea Necchi
职业:
肿瘤科医生
语言:
EN
IT

您需要预约吗?

联系我们,我们将为您妥善安排。
立即预约医生。
查看医生的可预约时间
发送请求

个人简介

Andrea Necchi教授是IRCCS Ospedale San Raffaele医学肿瘤科的肿瘤科医生,该科由Stefano Cascinu教授领导。同时,他还担任泌尿生殖系统肿瘤战略性肿瘤研究项目主任。

此外,他还是米兰Vita-Salute San Raffaele大学医学肿瘤学副教授。

他的培训经历始于2004年在米兰大学以优异成绩获得医学与外科学位,随后于2008年在同一所大学以优异成绩完成医学肿瘤学专科培训。在专科培训期间,他开展了针对血液系统肿瘤治疗以及实体肿瘤高剂量化疗治疗的专项培训。此外,同样在专科培训阶段,他开始专注于泌尿系统肿瘤的多学科治疗。

从临床和科研角度来看,教授主要专注于泌尿系统肿瘤的治疗。在其职业生涯中,他是全球最早开发浸润性膀胱肿瘤术前免疫治疗策略的专家之一;并在睾丸肿瘤和阴茎肿瘤领域积累了重要的临床和研究经验。

近期,他与其协调的工作组开展了针对肾脏和前列腺肿瘤的临床研究。事实上,该工作组已获得开展I期临床研究的认证,研究目标是治疗泌尿系统肿瘤患者。目前,该科室可向患者提供约30项临床研究方案。整个临床和转化研究活动均基于多学科方法开展,尤其与泌尿外科密切合作。

在其职业生涯中,他曾获得多项奖项,包括:

  • 07/2011:由Michelangelo基金会颁发的1st Gianni Bonadonna Prize for New Drug Development in Oncology。
  • 11/2010:由米兰Fondazione IRCCS Istituto Nazionale dei Tumori颁发的Young Researchers Award。
  • 05/2012、09/2012、02/2013、02/2015:由美国临床肿瘤学会(ASCO)Conquer Cancer Foundation颁发的4项Merit Award。
  • 2018、2019:欧洲肿瘤内科学会(ESMO)颁发的2项Merit Award。
  • 自2026年7月24日起,他被授予美国临床肿瘤学会Fellow称号(FASCO)。

他是以下国际协会年度会议科学委员会成员:

  • 美国临床肿瘤学会(ASCO)
  • 欧洲肿瘤内科学会(ESMO)
  • 欧洲泌尿外科学会(EAU)
  • 泌尿肿瘤学会(SUO)
  • 国际泌尿外科学会(SIU)
  • 欧洲多学科泌尿学会议(EMUC)

他是泌尿系统肿瘤II期和III期临床研究Global Steering Committee成员,并是Global Society of Rare Genitourinary Tumors的联合创始人兼副主席。该国际协会旨在推动罕见泌尿生殖系统肿瘤领域的研究、教育和信息传播。他也是European Association of Urology – Research Foundation(EAU-RF)的董事会成员。

他是意大利膀胱肿瘤协会Palinuro(Pazienti Liberi dalle Neoplasie Uroteliali)的联合创始人。同时,他也与ANTURE(Associazione Nazionale Tumori del Rene)合作。

他是570篇专业科学期刊论文和书籍章节的作者及合著者。其H指数为36。

出版物

最新出版物

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
J Clin Oncol. 2018 Dec 1;36(34):3353-3360.
Necchi A, Anichini A, Raggi D, et al.
Impact of Molecular Subtyping and Immune In ltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
Eur Urol. 2020 Jun;77(6):701-710.
Necchi A, Raggi D, Gallina A, et al.
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy?
First survival outcomes from the PURE-01 study. Ann Oncol. 2020 Dec;31(12):1755-1763.
Bandini M, Gibb EA, Gallina A, et al.
Erda tinib in Locally Advanced or Metastatic Urothelial Carcinoma
N Engl J Med. 2019 Jul 25;381(4):338-348.
Loriot Y, Necchi A, Park SH, et al.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Lancet Oncol 2012;8:810-16.
Necchi A, Mariani, Zaffaroni N, et al.
Proof of activity of anti-EGFR targeted therapy for relapsed squamous-cell carcinoma of the penis
J Clin Oncol 2011;29:2178-84.
Necchi A, Nicolai N, Colecchia C et al.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
N Engl J Med. 2017 Mar 16;376(11):1015-1026.
Bellmunt J, de Wit R, Vaughn DJ, et al.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatinineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol
2021 Jun;22(6):872-882.
Yu EY, Petrylak DP, O'Donnell PH, et al.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol. 2020 Dec;21(12):1574-1588.
Powles T, van der Heijden MS, Castellano D, et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Lancet Oncol. 2017 Mar;18(3):312-322.
Sharma P, Retz M, Siefker-Radtke A, et al.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Lancet. 2016 May 7;387(10031):1909-20.
Rosenberg JE, Hoffman-Censits J, Powles T, et al.
Atezolizumab as  rst-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet. 2017 Jan 7;389(10064):67-76.
Balar AV, Galsky MD, Rosenberg JE, et al.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Lancet. 2017 Nov 18;390(10109):2266-2277.
Petrylak DP, de Wit R, Chi KN, et al.
Contrasting genomic pro les from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer
Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865. Online ahead of print.
Necchi A, Cucchiara V, Grivas P, et al.
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumabur
Eur Urol. 2021 Aug;80(2):149-159.
Necchi A, de Jong JJ, Raggi D, et al.